Diabetic Peripheral Neuropathy Market to Reach $5.84B by 2030 at 8.8% CAGR
The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
What Is The Forecasted Market Size Trajectory Of The Diabetic Peripheral Neuropathy Market From 2026 To 2030?
The diabetic peripheral neuropathy market has experienced substantial expansion over recent years. This market is projected to grow from $3.83 billion in 2025 to $4.18 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 9.0%. The expansion observed in the historic period can be attributed to a high incidence of diabetic nerve damage, delayed clinical intervention, limited awareness of early symptoms, dependence on analgesics, and an increasing duration of diabetes.
The diabetic peripheral neuropathy market is projected to experience robust expansion over the coming years, with its size forecast to reach $5.84 billion in 2030, demonstrating a compound annual growth rate (CAGR) of 8.8%. This anticipated growth throughout the forecast period is primarily driven by advancements in screening technologies, the increasing availability of specialty care centers, the innovation of novel pain therapies, enhanced patient education initiatives, and a growing elderly diabetic demographic. Significant trends expected during this period encompass a rising demand for peripheral neuropathy treatments, a heightened focus on the early detection of sensory loss, the wider implementation of combination pain management strategies, increasing adoption of therapies aimed at long-term symptom control, and more extensive patient screening and monitoring.
Access Your Free Sample Report For In-Depth Market Analysis:
What Key Factors Are Shaping The Diabetic Peripheral Neuropathy Market Landscape?
The rising incidence of obesity-related health problems is anticipated to fuel the expansion of the diabetic peripheral neuropathy market moving forward. Obesity is defined as a medical state marked by an excessive accumulation of body fat that can compromise health and elevate the risk of various chronic diseases. The growth in health concerns linked to obesity stems from increased awareness, lifestyle adjustments, and a growing demand for preventive and treatment solutions, leading to higher healthcare demand. Diabetic peripheral neuropathy is beneficial for obesity management. It offers crucial insights into nerve damage caused by obesity-related conditions, thereby guiding targeted interventions to enhance overall patient well-being and quality of life. For instance, in September 2024, data from the Centers for Disease Control and Prevention (CDC), a US-based government public health agency, showed that 23 states reported an adult obesity prevalence of 35% or higher in 2023, and all 50 states recorded obesity rates of at least 20%. Consequently, the escalation of obesity-related health issues is stimulating growth in the diabetic peripheral neuropathy market.
How Is The Diabetic Peripheral Neuropathy Market Organized By Segment Classification?
The diabetic peripheral neuropathy market covered in this report is segmented –
1) By Disease: Type 2 Diabetic Peripheral Neuropathy, Type 1 Diabetic Peripheral Neuropathy
2) By Treatment: Pain Management Drugs, Gene Therapies
3) By Therapy: Antidepressants, Anticonvulsants
4) By Patient Population: Adult Patients, Geriatric Patients
Subsegments:
1) By Type 2 Diabetic Peripheral Neuropathy: Sensory Neuropathy, Motor Neuropathy, Autonomic Neuropathy
2) By Type 1 Diabetic Peripheral Neuropathy: Distal Symmetric Neuropathy, Mononeuropathy, Polyradiculopathy
What Market Trends Are Affecting The Diabetic Peripheral Neuropathy Market?
Leading companies within the diabetic peripheral neuropathy market are prioritizing technological advancements, such as NaV1.8 pain signal inhibitors, to offer patients sophisticated, non-opioid treatments aimed at enhancing pain management and overall quality of life. A NaV1.8 pain signal inhibitor functions as a specialized medication, blocking the NaV1.8 sodium channel—a key transmitter of pain signals in sensory neurons—to deliver relief from acute and neuropathic pain without the use of opioids. For instance, in April 2024, Vertex Pharmaceuticals Incorporated, a US-based biotech company, declared progress in its suzetrigine pain program, which includes commencing a Phase 3 pivotal program for treating pain linked to diabetic peripheral neuropathy (DPN). Suzetrigine, a selective NaV1.8 pain signal inhibitor, has shown promising results in earlier studies and recently secured Food and Drug Administration (FDA), a US-based federal agency, breakthrough therapy designation for diabetic Peripheral Neuropathy (DPN) pain management.
Who Are The Industry Participants Involved In The Diabetic Peripheral Neuropathy Market?
Major companies operating in the diabetic peripheral neuropathy market are Pfizer Inc., Merck & Co. Inc., GlaxoSmithKline plc., Eli Lilly and Company, Sun Pharmaceutical Industries Limited, Lupin Pharmaceuticals Inc., Chemie Grünenthal GmbH, Alkem Laboratories Limited, Acorda Therapeutics Inc., NeuroMetrix Inc., Johnson & Johnson, Novartis AG, Teva Pharmaceutical Industries Ltd., Abbott Laboratories, AstraZeneca plc., Bayer AG., UCB SA., Regeneron Pharmaceuticals Inc., Roche., Sanofi S.A., Amgen Inc., Lexicon Pharmaceuticals Inc., Daiichi Sankyo Co. Ltd.
Get The Full Diabetic Peripheral Neuropathy Market Report:
Which Region Dominates The Diabetic Peripheral Neuropathy Market By Market Share?
North America was the largest region in the diabetic peripheral neuropathy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the diabetic peripheral neuropathy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Diabetic Peripheral Neuropathy Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Diabetic Peripheral Neuropathy Market 2026, By The Business Research Company
Non Proliferative Diabetic Retinopathy Market Report 2026
Peripheral Neuropathy Market Report 2026
https://www.thebusinessresearchcompany.com/report/peripheral-neuropathy-global-market-report
Diabetic Retinopathy Market Report 2026
https://www.thebusinessresearchcompany.com/report/diabetic-retinopathy-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
